ERASMM trial (elranatamab): what clinicians have said so far
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
- NCT06183489 ↗
- Active, not recruiting
- European Myeloma Network B.V.
- Focused size, estimated: 1–150 verified statements once built
Discussed at: 2026 ASCO Annual Meeting, EHA2026 Congress
We haven't built an HCP commentary report on ERASMM (elranatamab in high-risk smoldering multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ERASMM so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 10 posts on X, typically up to 44 once built |
The trial
ClinicalTrials.gov- Official title
- A Multi-center, Open-label, Phase 2 Study of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- Elranatamab
- Arms
- Elranatamab · Experimental
- Enrollment
- 50 (estimated)
- Primary outcomes
- Complete Remission (CR) rate
- Sponsor
- European Myeloma Network B.V. with Pfizer, EMN Trial Office S.r.l. Impresa Sociale
- Start
- May 14, 2024
- Primary completion
- Jul 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06183489 · updated Sep 2, 2026